user
menu
letter
Sign InRegister
langEnglisharrow

TGF-beta RI

TGF-beta RI

TGF-beta RI Overview

Molecule Name
Transforming growth factor beta receptor 1
Synonyms
TGFR-1, ALK-5, TGF-beta receptor type-1, Activin receptor-like kinase 5
Drug Development Progress
Drugs in Clinical Trials7
Approved Drugs0
Highest Development StagePhase 3 Clinical
Target Synonym
EC 2.7.11，TGF-beta type I receptor，Serine/threonine-protein kinase receptor R4，TGFBR1，Activin A receptor type II-like protein kinase of 53kD，Transforming Growth Factor Beta Receptor 1，Transforming Growth Factor-Beta Receptor Type I，Activin A Receptor Type II-Like Kinase， 53kDa，Activin Receptor-Like Kinase 5，TGFR-1，ALK-5，ALK5，SKR4，Mutant Transforming Growth Factor Beta Receptor I，TGF-Beta Receptor Type-1，TGF-Beta Receptor Type I，EC 2.7.11.30，ACVRLK4，LDS1A，LDS2A，AAT5，LDS1，TBRI，ESS1，MSSE，TbetaR-I，Transforming Growth Factor Beta Receptor I，Multiple Self-Healing Squamous Epithelioma，TBR-I，Receptor， Transforming Growth Factor-beta Type I，EC:2.7.11.30
Background
TGF type I receptor also called the activin receptor-like kinase 5 (ALK5) and involved in TGF signaling. TGFβ signaling is mediated by the interaction of TGFβ ligands (TGFβ 1, 2 or 3) with cell surface receptors, the TGF type I, type II and type III receptors. Signaling is initiated by binding of TGF to the TGF type II receptor forming a ligand-receptor complex which interacts with the TGF type I receptor.

TGF-beta RI Product List

Species
  • Human（2）
Tag
  • Fc Tag（1）
  • Llama IgG Fc Tag（1）
Host
  • HEK293（2）
Conjugate
  • Unconjugated（2）
Grade
  • RUO（2）
Low Endotoxin
  • Yes（1）
  • No（1）
MoleculeCat. No.Product NameSpeciesHostStructurePurityActivitySize&Price
TGF-beta RI
AIDD‑Ready
TG1-H5254
Human TGF-beta RI Protein, Fc Tag, low endotoxin (MALS verified)
Human
HEK293
MALSSDS-PAGE
SPR

$360.00

100ug
TGF-beta RI
AIDD‑Ready
TG1-H5259
Human TGFR-1 / ALK-5 / TGF-beta receptor type-1 Protein, Llama IgG2b Fc Tag (SPR verified)
Human
HEK293
SDS-PAGE
SPR

$390.00

100ug
You Have Viewed 1-2 Of 2 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Product InquiryRequest Customization
Asset Licensing Opportunity
Resources

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
GalunisertibLY-2157299Phase 3 ClinicalEli Lilly And Company
Amyotrophic Lateral Sclerosis; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Glioblastoma; Glioma; Liver Neoplasms; Metastatic breast cancer; Myelodysplastic Syndromes; Nasopharyngeal Carcinoma; Neoplasm Metastasis; Neoplasms; Pancreatic Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Rectal Neoplasms; Solid tumours; Triple Negative Breast Neoplasms
Details
GF-101GFH-018; GF-101; GFH018Phase 2 ClinicalGenfleet Therapeutics (Shanghai) Co Ltd
Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Liver Neoplasms; Pancreatic Neoplasms; Solid tumours
Details
Tosposertib phosphateTU-2218; NCE401; NCE-401Phase 2 ClinicalTiumBio Co Ltd
Idiopathic Pulmonary Fibrosis; Solid tumours
Details
OntunisertibORG-129; AGMB-129Phase 2 ClinicalOrigo Biopharma Sociedad Litmitada
Crohn Disease
Details
TRK-250TRK-250; BNC-1021Phase 1 ClinicalBonac Corp
Idiopathic Pulmonary Fibrosis
Details
OxinsetiSH-3051Phase 1 ClinicalNanjing Sanhome Pharmaceutical Co Ltd
Liver Neoplasms; Solid tumours
Details
AGMB-447AGMB-447; ORG-447Phase 1 ClinicalAgomAb Therapeutics NV
Idiopathic Pulmonary Fibrosis
Details
Customer Reviews